Zobrazeno 1 - 10
of 118
pro vyhledávání: '"Daniel J. Booser"'
Autor:
Fatma Nihan Akkoc Mustafayev, Diane D. Liu, Angelica M. Gutierrez, John E. Lewis, Nuhad K. Ibrahim, Vicente Valero, Daniel J. Booser, Jennifer K. Litton, Kimberly Koenig, Dihua Yu, Nour Sneige, Banu K. Arun
Publikováno v:
European Journal of Breast Health, Vol 19, Iss 4, Pp 267-273 (2023)
Objective:Risk-reducing therapy with selective estrogen receptor (ER) modulators and aromatase inhibitors reduce breast cancer risk. However, the effects are limited to ER-positive breast cancer. Therefore, new agents with improved toxicity profiles
Externí odkaz:
https://doaj.org/article/007df5a2dfff4116b58ca4a6c94fbe74
Autor:
Blessie Elizabeth Nelson, Sadia Saleem, Senthil Damodaran, Neeta Somaiah, Sarina Piha‐Paul, Julia Ann Moore, Bulent Yilmaz, Deby Ogbonna, Daniel D. Karp, Ecaterina Dumbrava, Apostolia M. Tsimberidou, David S. Hong, Jordi Rodon Ahnert, Denái R. Milton, Xiaofeng Zheng, Daniel J. Booser, Nuhad K. Ibrahim, Anthony P. Conley, Priya Bhosale, Cristhiam M. Rojas Hernandez, Debasish Tripathy, Aung Naing, Funda Meric‐Bernstam
Publikováno v:
Cancer.
Autor:
Blessie Elizabeth Nelson, Sadia Saleem, Senthil Damodaran, Neeta Somaiah, Sarina Anne Piha-Paul, Julia Ann Moore, Bulent Yilmaz, Daniel D. Karp, Ecaterina Elena Dumbrava, Apostolia Maria Tsimberidou, David S. Hong, Jordi Rodon Ahnert, Daniel J. Booser, Nuhad K. Ibrahim, Anthony Paul Conley, Priya Bhosale, Cristhiam Mauricio Rojas Hernandez, Debu Tripathy, Aung Naing, Funda Meric-Bernstam
Publikováno v:
Journal of Clinical Oncology. 40:3108-3108
3108 Background: Selinexor (KPT-330) is potent inhibitor of Exportin-1. In vitro, Selinexor was found to be synergistic with eribulin in triple negative breast cancer (TNBC) cell lines and enhanced antitumor activity of eribulin in TNBC patient-deriv
Autor:
Debu Tripathy, Ricardo H. Alvarez, Rashmi Krishna Murthy, Naoto T. Ueno, Carlos H. Barcenas, Jimin Wu, Jangsoon Lee, Richard Piekarz, Toshiaki Iwase, S. Jackson, Stacy L. Moulder, Sharon H. Giordano, Jeffrey A. Moscow, Abenaa M. Brewster, Vicente Valero, Darren W. Davis, Jie Willey, Nuhad K. Ibrahim, Yu Shen, Powel H. Brown, Bora Lim, Daniel J. Booser
Publikováno v:
British Journal of Cancer
Background Human epidermal growth factor 2 (HER2) is an effective therapeutic target in breast cancer; however, resistance to anti-HER2 agents such as trastuzumab and lapatinib develops. In a preclinical model, an HDAC inhibitor epigenetically revers
Autor:
Ya Zhang, Dilip Giri, Esmeralda Celia Marginean, W. Fraser Symmans, Ioanna Laïos, Rashmi Krishna Murthy, Christos Hatzis, Jennifer K. Litton, Ravi Murthy, Alda L. Tam, Agnes Viale, Eleni Andreopoulou, Danielle N. Kwiatkowski, Rebekah Gould, Tsung-Heng Tsai, Tari A. King, Chunxiao Fu, Vicente Valero, Bruno Valentin Sinn, Yun Gong, Daniel J. Booser, Victor P. Andrade, Roberto Salgado, Rosanna Lau, Rachel M. Layman, Christos Sotiriou
Publikováno v:
npj Breast Cancer, Vol 5, Iss 1, Pp 1-8 (2019)
NPJ breast cancer, 5 (1
NPJ breast cancer, 5 (1
There is a clinical need to predict sensitivity of metastatic hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer to endocrine therapy, and targeted RNA sequencing (RNAseq) offers diagnostic potential to measure both transcription
Autor:
Francisco J. Esteva, Gabriel N. Hortobagyi, Sharon H. Giordano, Rashmi Krishna Murthy, Abenaa M. Brewster, Robert C. Bast, Stacy L. Moulder, Gaiane M. Rauch, Wei Yang, Ronald S. Walters, Daniel J. Booser, Vicente Valero, Clinton Yam, James L. Murray, Banu Arun
Publikováno v:
Investigational New Drugs. 36:1103-1109
Background Imatinib mesylate is a potent inhibitor of the Abl, KIT and platelet derived growth factor (PDGF) receptor tyrosine kinases. Preclinical data suggest that combining imatinib mesylate with anti-estrogen therapy may be synergistic in hormone
Autor:
Ricardo H. Alvarez, Daniel J. Booser, Abigail S. Caudle, JM Reuben, Kimberly B. Koenig, A Cyriac, Mariana Chavez-MacGregor, J. Schwartz Gomez, Joe Ensor, Jennifer K. Litton, V. Valero, Savitri Krishnamurty, Nuhad K. Ibrahim, Simona F. Shaitelman, Gary J. Whitman
Publikováno v:
Cancer Research. 76:P1-14
Background: Neoadjuvant chemotherapy (NACT) is an integral component for locally advanced and large operable breast cancer. The sequence of taxanes followed by anthracyclines has been the standard of care for almost 20 years. Eribulin (E) is a synthe
Autor:
Ricardo H. Alvarez, Bora Lim, V. Valero, Ronald S. Walters, S. Jackson, Sharon H. Giordano, Abenaa M. Brewster, Daniel J. Booser, Powel H. Brown, Carlos H. Barcenas, Ravi Murthy, Debu Tripathy, NT Ueno, Nuhad K. Ibrahim, Jie Willey
Publikováno v:
Cancer Research. 76:P4-14
Background: Our in vitro and in vivo preclinical data showed that entinostat enhances the efficacy of lapatinib in HER2 positive (HER2+) breast cancer cells via FOXO3-mediated Bim1 expression, which resulted in enhanced apoptosis in HER2 targeted the
Autor:
Constance Albarracin, Kimberly B. Koenig, Filip Janku, Vivek Subbiah, Jennifer K. Litton, Razelle Kurzrock, Funda Meric-Bernstam, Jennifer J. Wheler, Michael Z. Gilcrease, Reva Basho, David S. Hong, V. Valero, James L. Murray, Thorunn Helgason, S. L. Moulder, Ravi Murthy, Daniel J. Booser, Mariana Chavez-MacGregor, Daniel D. Karp, Nuhad K. Ibrahim
Publikováno v:
Cancer Research. 76:P3-14
Background: Approximately 30% of TNBCs are characterized by microarray as claudin-low, mesenchymal or mesenchymal stem cell-like and, unlike basal TNBCs, these tumors frequently harbor aberrations in the PI3K/AKT/mTOR axis, raising the possibility of
Autor:
Sriram Yennu, Kenneth R. Hess, Carolina Diaz Hernandez, Bora Lim, Zhanni Lu, James M. Reuben, Diane D. Liu, Karen Basen-Engquist, Daniel J. Booser, Naifa L. Busaidy, Eduardo Bruera, Janet L. Williams, Vicente Valero
Publikováno v:
Journal of Clinical Oncology. 37:110-110
110 Background: Cancer-related-fatigue (CRF) is the most debilitating symptom in patients with advanced cancer. Physical activity (PA) improves CRF with lower adherence in advanced cancer. Dexamethasone (Dex) improves CRF but has long-term side effec